When considering clinical efficacy and safety, camrelizumab combined with chemotherapy (camre-chemo) emerges as an outstanding first-line therapeutic option for advanced ESCC patients without selected PD-L1 expression. The gene discussed is CD274; the disease is esophageal squamous cell carcinoma.